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1. INTRODUCTION {#dom13048-sec-0005}
===============

In people with type 1 diabetes (T1DM), long‐term maintenance of blood glucose levels close to normal is associated with a reduction in progression of microvascular complications and in all‐cause mortality.[1](#dom13048-bib-0001){ref-type="ref"}, [2](#dom13048-bib-0002){ref-type="ref"} Current guidelines recommend insulin analogues for people with T1DM, because of the lower associated risk of hypoglycaemia compared with optimized insulin therapy with human insulin.[3](#dom13048-bib-0003){ref-type="ref"} Nevertheless, blood glucose control remains suboptimal in many people,[4](#dom13048-bib-0004){ref-type="ref"}, [5](#dom13048-bib-0005){ref-type="ref"} with described barriers including concerns about hypoglycaemia, flexibility of injection schedule and weight gain.[5](#dom13048-bib-0005){ref-type="ref"} Some of these difficulties may be related to action profiles of conventional extended‐acting insulins and the first‐generation long‐acting insulin analogues.[5](#dom13048-bib-0005){ref-type="ref"}, [6](#dom13048-bib-0006){ref-type="ref"}

In people with type 2 diabetes (T2DM) already receiving insulin, the more stable and prolonged pharmacokinetic and pharmacodynamic profiles of insulin glargine 300 U/mL (Gla‐300) vs those of glargine 100 U/mL (Gla‐100)[7](#dom13048-bib-0007){ref-type="ref"} translate into sustained glycaemic control for 1 year, with less nocturnal hypoglycaemia.[8](#dom13048-bib-0008){ref-type="ref"}, [9](#dom13048-bib-0009){ref-type="ref"} In T1DM in the EDITION 4 clinical trial, 549 people were randomized to Gla‐300 or Gla‐100 as basal insulin, and to morning or evening injection.[10](#dom13048-bib-0010){ref-type="ref"} The primary 6‐month results showed equivalent glycaemic control and a lower risk of nocturnal hypoglycaemia with Gla‐300 vs Gla‐100 during the first 8 weeks.[10](#dom13048-bib-0010){ref-type="ref"} Glucose profiles, rates of hypoglycaemia and adverse events were comparable, irrespective of morning or evening Gla‐300 injection,[10](#dom13048-bib-0010){ref-type="ref"} suggesting that Gla‐300 provides the freedom to choose a morning or evening injection schedule without compromising glycaemic control or increasing hypoglycaemia. In the current 6‐month, pre‐planned continuation of EDITION 4, we investigated the safety, tolerability and efficacy of Gla‐300 compared with Gla‐100, given morning or evening, over 12 months.

2. MATERIALS AND METHODS {#dom13048-sec-0006}
========================

2.1. Study design and participants {#dom13048-sec-0007}
----------------------------------

EDITION 4 was a multicentre, 4‐arm, parallel‐group, phase 3a study in people with T1DM who were randomized (1:1:1:1) to once‐daily Gla‐300 or Gla‐100 (both Sanofi, Paris, France), injected morning or evening, while continuing meal‐time insulin (NCT01683266).[10](#dom13048-bib-0010){ref-type="ref"} People completing the 6‐month main study period continued open‐label Gla‐300 or Gla‐100 once daily in the morning or evening, as previously randomized, for a further 6 months. The EDITION 4 study design was reported in detail in the primary 6‐month report.[10](#dom13048-bib-0010){ref-type="ref"}

Participants were aged ≥18 years, had T1DM for \>1 year, had HbA1c in the range of 7.0 %‐units to 10.0 %‐units (53 to 86 mmol/mol) and had spent \>1 year on basal insulin combined with a meal‐time insulin analogue. Gla‐300 was given subcutaneously using a modified TactiPen pen‐injector (Sanofi) that allowed 1.5 U dose increments, while Gla‐100 was given subcutaneously using the SoloSTAR pen (Sanofi), allowing 1 U dose increments.

Basal insulin was titrated to a pre‐breakfast self‐monitored plasma glucose (SMPG) level of 4.4 to 7.2 mmol/L (80--130 mg/dL).[10](#dom13048-bib-0010){ref-type="ref"} Dose adjustments of basal insulin were made weekly, and no more often than every 3 to 4 days.[10](#dom13048-bib-0010){ref-type="ref"} Meal‐time insulin was continued with a target range of \<8.9 mmol/L (160 mg/dL) for 2‐hour postprandial plasma glucose, adjusted at investigator/participant discretion.[10](#dom13048-bib-0010){ref-type="ref"}

The study was approved by relevant review boards/ethics committees, and was performed in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines. All participants provided written informed consent.[10](#dom13048-bib-0010){ref-type="ref"}

2.2. Outcomes {#dom13048-sec-0008}
-------------

Efficacy outcomes included change from baseline to month 12 in HbA1c, central‐laboratory‐measured fasting plasma glucose (FPG), pre‐breakfast SMPG, 8‐point SMPG profiles and insulin dose (basal and meal‐time).

Hypoglycaemia assessments included the percentage of participants reporting ≥1 event and event rates. Events were categorized using American Diabetes Association (ADA) definitions[11](#dom13048-bib-0011){ref-type="ref"}: "severe" hypoglycaemia was defined as an event that required assistance; "documented symptomatic" hypoglycaemia required typical symptoms with a plasma glucose concentration ≤3.9 mmol/L (≤70 mg/dL); "confirmed or severe" hypoglycaemia included symptomatic or asymptomatic events with plasma glucose concentration ≤3.9 mmol/L (≤70 mg/dL) and "severe" events. A pre‐planned sensitivity analysis using \<3.0 mmol/L (\<54 mg/dL) was done. "Night‐time" was defined as 0:00 to 5:59 [am]{.smallcaps}.

Treatment‐emergent adverse events (AEs) and body weight were systematically recorded at each visit. Participant‐reported satisfaction with treatment and perception of occurrence of hypo‐ and hyper‐glycaemia were assessed using the Diabetes Treatment Satisfaction Questionnaire (status) (DTSQs), and health‐related quality of life was assessed with the EQ‐5D questionnaire.[12](#dom13048-bib-0012){ref-type="ref"}, [13](#dom13048-bib-0013){ref-type="ref"} Behaviours and worries related to hypoglycaemia were assessed with the Hypoglycaemia Fear Survey‐II (HFS II).[14](#dom13048-bib-0014){ref-type="ref"}

2.3. Data analysis and statistics {#dom13048-sec-0009}
---------------------------------

Efficacy analyses were based on the modified intention‐to‐treat (mITT) population, defined as all randomized participants who received ≥1 dose of study insulin and had a baseline and at least one post‐baseline efficacy assessment. Continuous endpoints were analysed using a mixed model for repeated measures (MMRM) approach, and categorical variables were analysed using a Cochran--Mantel--Haenszel (CMH) method.[10](#dom13048-bib-0010){ref-type="ref"}

Hypoglycaemia and safety analyses were based on the safety population: all participants randomized and receiving ≥1 treatment dose. Change in body weight was assessed using an analysis of covariance (ANCOVA) model. Calculation of rate ratio for hypoglycaemic event rate was done using an over‐dispersed Poisson regression model. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 17.0.

3. RESULTS {#dom13048-sec-0010}
==========

3.1. Participants {#dom13048-sec-0011}
-----------------

All 549 people with T1DM who were randomized to Gla‐300 (n = 274) or Gla‐100 (n = 275) received study insulin (the safety population) (Figure [S1](#dom13048-supitem-0001){ref-type="supplementary-material"}). All participants randomized to Gla‐300 met criteria for the mITT population (above), but there was no baseline or post‐baseline efficacy data for 2 Gla‐100 participants (n = 273 mITT participants). In the Gla‐300 group, 136 and 138 participants received morning and evening injections, respectively, and in the Gla‐100 group, 135 and 138 participants received morning and evening injections, respectively.

The 12‐month study period was completed by 219 participants (80%) in the Gla‐300 group and by 225 (82%) in the Gla‐100 group (Figure [S1](#dom13048-supitem-0001){ref-type="supplementary-material"}). Most discontinuations occurred in the first 6 months of the study (Gla‐300, 43; Gla‐100, 39), with few during the second 6 months (Gla‐300, 12; Gla‐100, 11). The most common explanation given for treatment discontinuation was "other reasons" (32 \[12%\] and 38 \[14%\] participants in the 2 groups, respectively), usually stating personal/family or job‐conflict reasons (17 and 25 participants, respectively).

Baseline characteristics have been fully described previously.[10](#dom13048-bib-0010){ref-type="ref"} Mean (SD) age of participants was 47.3 (13.7) years; 57% were male; BMI was 27.6 (5.1) kg/m^2^; and body weight was 81.8 (18.7) kg. Duration of T1DM was 21.0 (12.9) years and most participants (82%) transferred from insulin glargine. Baseline HbA1c was 8.13 (0.8) %‐units (65.3 \[9\] mmol/mol) and laboratory‐measured clinic FPG was 10.7 (4.4) mmol/L (193 \[79\] mg/dL). No notable differences in baseline characteristics were observed between the insulin groups or in morning vs evening injection.

3.2. Insulin dose {#dom13048-sec-0012}
-----------------

Mean (SD) daily basal insulin dose prior to the study was 0.38 (0.17) U/kg (32.3 \[20.8\] U) in the Gla‐300 group and 0.37 (0.15) U/kg (30.6 \[15.2\] U) in the Gla‐100 group. These doses were lower at day 1 ("baseline") (Table [S1](#dom13048-supitem-0001){ref-type="supplementary-material"}) and then increased to month 12 in both groups (Gla‐300 to 0.48 \[0.22\] U/kg; Gla‐100 to 0.40 \[0.18\] U/kg), mostly during the first 8 weeks (Figure [1](#dom13048-fig-0001){ref-type="fig"}A). The meal‐time total insulin dose remained stable in both groups throughout the study.

![Time course of daily insulin dose (A), body weight change from baseline (B), glycated haemoglobin (C), glycated haemoglobin by basal insulin injection time (D), laboratory‐measured clinic FPG (E), laboratory‐measured clinic FPG by basal insulin injection time (F), SMPG profiles (G) and SMPG profiles by basal insulin injection time (H) over 12 months of treatment with Gla‐300 or Gla‐100. mITT population, except body weight change (safety population). Baseline body weight = 81.9 and 81.8 kg for Gla‐300 and Gla‐100 groups, respectively. Mean ± SE. BL, baseline; D, day; FPG, laboratory‐measured clinic fasting plasma glucose; LOV, last on‐treatment value; M, month; mITT, modified intention‐to‐treat; SE, standard error; SMPG, self‐monitored plasma glucose; W, week](DOM-20-121-g001){#dom13048-fig-0001}

Mean daily basal insulin doses at 12 months in the Gla‐300 group were 0.51 (0.23) U/kg for morning injections and 0.46 (0.21) U/kg for evening injections; corresponding doses in the Gla‐100 group were 0.45 (0.18) U/kg and 0.36 (0.17) U/kg (Table [S1](#dom13048-supitem-0001){ref-type="supplementary-material"}). Total daily insulin dose at month 12 for morning injections was 15.6% higher in the Gla‐300 group (0.87 \[0.33\] U/kg) than in the Gla‐100 group (0.75 \[0.25\] U/kg), and for evening injections it was 16.8% higher (0.82 \[0.36\] vs 0.70 \[0.28\] U/kg). At month 12, while basal insulin was 58.2% of total dose with Gla‐300 and, similarly, 59.5% with Gla‐100 in the morning injection groups, these proportions were 56.1% and 51.7% in the evening groups.

3.3. Blood glucose control {#dom13048-sec-0013}
--------------------------

Mean HbA1c decreased similarly from baseline to month 12 in the Gla‐300 and Gla‐100 groups (Figure [1](#dom13048-fig-0001){ref-type="fig"}C and Table [1](#dom13048-tbl-0001){ref-type="table-wrap"}). LS mean difference in change from baseline (Gla‐300 vs Gla‐100) was 0.02 (95% CI, −0.13 to 0.17) %‐units (0.2 \[95% CI,−1.5 to 1.9\] mmol/mol), with most of the decrease by week 12. During the second 6‐month period, mean HbA1c increased similarly in the 2 groups, remaining below baseline and ending at 7.86 (SD, 1.03) %‐units (62.4 \[SD, 11.3\] mmol/mol) and 7.86 (SD, 0.84) %‐units (62.4 \[SD, 9.2\] mmol/mol) in the Gla‐300 and Gla‐100 groups, respectively (Figure [1](#dom13048-fig-0001){ref-type="fig"}C). When comparing morning and evening injection (Figure [1](#dom13048-fig-0001){ref-type="fig"}D), there was no difference in HbA1c change over 12 months for the Gla‐100 group, but a significantly larger decrease was observed in the Gla‐300 morning group (ending at 7.76 \[SD, 0.98\] %‐units \[61.4 (SD, 10.7) mmol/mol\]) than in the Gla‐300 evening group (ending at 7.96 \[SD, 1.07\] %‐units \[63.5 (SD, 11.7) mmol/mol\]) (LS mean difference \[95% CI\] in change from baseline, −0.25 \[−0.47 to −0.04\] %‐units (−2.7 \[−5.2 to −0.4\] mmol/mol).

###### 

Glycaemic control measures over 12 months of treatment with Gla‐300 or Gla‐100

                                           Gla‐300         Gla‐100
  --------------------------------- ---------------------- --------------
  **HbA1c (%)**                                            
  Baseline                               8.13 (0.77)       8.12 (0.79)
  Month 12                               7.86 (1.03)       7.86 (0.84)
  Change                                 −0.20 (0.06)      −0.22 (0.06)
  LS mean difference (95% CI)        0.02 (−0.13 to 0.17)  
  **HbA1c (mmol/mol)**                                     
  Baseline                                65.3 (8.4)       65.2 (8.6)
  Month 12                               62.4 (11.3)       62.4 (9.2)
  Change                                  −2.2 (0.6)       −2.4 (0.6)
  LS mean difference (95% CI)         0.2 (−1.5 to 1.9)    
  **FPG (mmol/L)**                                         
  Baseline                               10.26 (4.14)      11.02 (4.46)
  Month 12                               9.79 (3.87)       9.63 (3.62)
  Change                                 −0.43 (5.22)      −1.39 (5.43)
  LS mean difference (95% CI)        0.18 (−0.55 to 0.90)  
  **Average 24‐h SMPG (mmol/L)**                           
  Baseline                               9.40 (2.54)       9.60 (2.34)
  Month 12                               9.02 (2.23)       8.99 (2.22)
  Change                                 −0.36 (2.77)      −0.58 (2.87)
  LS mean difference (95% CI)        0.12 (−0.34 to 0.58)  
  **Pre‐breakfast SMPG (mmol/L)**                          
  Baseline                               8.91 (2.56)       9.28 (2.51)
  Month 12                               8.44 (2.29)       8.40 (2.09)
  Change                                 −0.32 (2.98)      −0.76 (2.71)

Abbreviations: FPG, laboratory‐measured clinic fasting plasma glucose; mITT, modified intention‐to‐treat; SD, standard deviation; SMPG, self‐monitored plasma glucose.

mITT population. Data are presented as mean (SD) unless otherwise mentioned.

A comparable reduction in laboratory‐measured clinic FPG from baseline to month 12 was seen with Gla‐300 and Gla‐100 (Figure [1](#dom13048-fig-0001){ref-type="fig"}E and Table [1](#dom13048-tbl-0001){ref-type="table-wrap"}). LS mean difference in change from baseline to month 12 was 0.18 (95% CI, −0.55 to 0.90) mmol/L (3.2 \[−10.0 to 16.3\] mg/dL). No effect of injection time was observed for the time course of laboratory‐measured FPG, with comparable reductions by month 12 for evening and morning groups (Figure [1](#dom13048-fig-0001){ref-type="fig"}F).

By month 12, plasma glucose levels on 8‐point SMPG profiles had decreased at all time points compared with baseline, and were comparable between the insulin groups, except at bedtime, with lower levels in the Gla‐300 group than in the Gla‐100 group (Figure [1](#dom13048-fig-0001){ref-type="fig"}G). At month 12, 8‐point SMPG profiles were comparable between morning and evening injection groups for Gla‐300 and Gla‐100 (Figure [1](#dom13048-fig-0001){ref-type="fig"}H), except pre‐breakfast, which was lower for evening injections than for morning injections with Gla‐300.

3.4. Hypoglycaemia {#dom13048-sec-0014}
------------------

Over 12 months nearly all participants (260 \[\~95%\] in each group) experienced ≥1 confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe hypoglycaemic event (risk ratio, 1.00 \[0.96--1.05\]); most participants (199 \[73%\] for Gla‐300 and 205 \[75%\] for Gla‐100) experienced ≥1 nocturnal event (risk ratio, 0.97 \[0.88--1.08\]) (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"}). Annualized rates of confirmed or severe hypoglycaemia were 75.9 events/person‐year in the Gla‐300 group and 68.8 events/person‐year in the Gla‐100 group at any time of day (24 hours) (rate ratio, 1.11 \[0.97--1.29\]), and 8.1 and 8.6 events/person‐year at night (rate ratio, 0.95 \[0.75‐1.20\]) (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"}). Cumulative mean events over time are given in Figure [2](#dom13048-fig-0002){ref-type="fig"}A,B. No trends with time are seen for nocturnal hypoglycaemia, but there were numerically more events at any time of day (24 hours) in the second 6‐month period with Gla‐300 compared with Gla‐100.

###### 

Population experiencing hypoglycaemia and event rates over 12 months

                                                                           Nocturnal hypoglycaemia (00:00--05:59 h)   Hypoglycaemia at any time (24 h)                                                              
  ------------------------------------------ ----------------------------- ------------------------------------------ ---------------------------------- ------ ------------ --------------- --------------- ------ ------------
  Total person‐years                                                       237.5                                      242.2                                                  237.5           242.2                  
  **Confirmed or severe hypoglycaemia**                                                                                                                                                                             
  ≤3.9 mmol/L (≤70 mg/dL)                    Participants, n (%)           199 (72.6)                                 205 (74.5)                         0.97   0.88--1.08   260 (94.9)      260 (94.5)      1.00   0.96--1.05
                                             Events, n (per person‐year)   1917 (8.1)                                 2079 (8.6)                         0.95   0.75--1.20   18 018 (75.9)   16 661 (68.8)   1.11   0.97--1.29
  \<3.0 mmol/L (\<54 mg/dL)                  Participants, n (%)           151 (55.1)                                 162 (58.9)                         0.94   0.81--1.08   225 (82.1)      231 (84.0)      0.98   0.91--1.06
                                             Events, n (per person‐year)   658 (2.8)                                  750 (3.1)                          0.90   0.68--1.20   4372 (18.4)     4068 (16.8)     1.11   0.91--1.35
  **Documented symptomatic hypoglycaemia**                                                                                                                                                                          
  ≤3.9 mmol/L (≤70 mg/dL)                    Participants, n (%)           176 (64.2)                                 174 (63.3)                         1.01   0.89--1.15   240 (87.6)      238 (86.5)      1.01   0.95--1.08
                                             Events, n (per person‐year)   1228 (5.2)                                 1379 (5.7)                         0.91   0.69--1.21   9286 (39.1)     8490 (35.1)     1.12   0.92--1.37
  \<3.0 mmol/L (\<54 mg/dL)                  Participants, n (%)           133 (48.5)                                 134 (48.7)                         1.00   0.84--1.18   202 (73.7)      206 (74.9)      0.98   0.89--1.09
                                             Events, n (per person‐year)   472 (2.0)                                  574 (2.4)                          0.85   0.61--1.18   2522 (10.6)     2559 (10.6)     1.01   0.80--1.28
  **Severe hypoglycaemia**                   Participants, n (%)           9 (3.3)                                    9 (3.3)                            1.01   0.44--2.28   25 (9.1)        31 (11.3)       0.81   0.50--1.33
                                             Events, n (per person‐year)   18 (0.08)                                  11 (0.05)                          1.57   0.49--5.04   87 (0.37)       57 (0.24)       1.61   0.57--4.58

Abbreviations: CI, confidence interval; RR, risk ratio for percentage of participants with ≥1 event, or rate ratio for events per person‐year.

Safety population.

![Cumulative mean number of confirmed (≤3.9 mmol/L \[≤70 mg/dL\]) or severe hypoglycaemic events per participant during 12 months of treatment with Gla‐300 or Gla‐100: A, events at any time of day (24 hours) and B, nocturnal events. Safety population](DOM-20-121-g002){#dom13048-fig-0002}

In the sensitivity analysis with a confirmation threshold of \<3.0 mmol/L (\<54 mg/dL), risk of hypoglycaemia and rate ratios remained statistically non‐significant (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"}). Similar patterns were observed using a definition of documented symptomatic hypoglycaemia, at either plasma glucose threshold (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"}). When hypoglycaemia rates were compared for the morning and evening groups statistical power was lower; thus, the central estimates were more erratic and confidence intervals were wider (Table [S2](#dom13048-supitem-0001){ref-type="supplementary-material"}). There were no statistically significant differences in any category of confirmed hypoglycaemia or documented symptomatic hypoglycaemia between study insulins.

At least 1 severe hypoglycaemic event at any time of day was reported by 25 (9%) participants in the Gla‐300 group and by 31 (11%) participants in the Gla‐100 group. Among these, 9 (3%) in each group experienced nocturnal events (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"}). Annualized rates (events/person‐year) of severe hypoglycaemia were 0.37 for Gla‐300 and 0.24 for Gla‐100 at any time of day (24 hours), and 0.08 and 0.05, respectively, during the night. Confidence intervals for study prevalence and event rates were very wide (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"} and Table [S2](#dom13048-supitem-0001){ref-type="supplementary-material"}).

3.5. Body weight {#dom13048-sec-0015}
----------------

Body weight increased in both treatment groups, but the statistically significant difference at 6 months in favour of Gla‐300[10](#dom13048-bib-0010){ref-type="ref"} was lost at 12 months (LS mean difference \[95% CI\] in change from baseline to month 12 \[last on‐treatment value\], −0.5 \[−1.1 to 0.1\] kg \[*P* = .098\]) (Figure [1](#dom13048-fig-0001){ref-type="fig"}B).

3.6. Participant‐reported outcomes {#dom13048-sec-0016}
----------------------------------

Mean change in total DTSQs scores from baseline to month 12 was similar in the 2 groups (Gla‐300, 1.3 \[SD, 5.3\]; Gla‐100, 1.6 \[SD, 4.9\]) (Table [S3](#dom13048-supitem-0001){ref-type="supplementary-material"}). Health status measured with EQ‐5D showed no change over 12 months in either group (Table [S3](#dom13048-supitem-0001){ref-type="supplementary-material"}). For HFS II scores, mean change from baseline to month 12 in total HFS II score was small and similar between groups (Gla‐300, −0.02 \[SD, 0.40\]; Gla‐100, −0.02 \[SD, 0.43\]) (Table [S3](#dom13048-supitem-0001){ref-type="supplementary-material"}).

3.7. Adverse events and insulin antibodies {#dom13048-sec-0017}
------------------------------------------

The number of participants who reported an AE during the 12‐month treatment period was similar in the Gla‐300 (198 \[72%\]) and Gla‐100 (187 \[68%\]) groups, as was the pattern of AEs. Serious AEs were reported by 27 (10%) Gla‐300 participants and 26 (10%) Gla‐100 participants, without a notable difference for any type of event. One participant in the Gla‐300 group, with pre‐existing cardiovascular disease, died of a cardiac event during the first 6‐month period.[10](#dom13048-bib-0010){ref-type="ref"} Five participants in the Gla‐300 group and 4 in the Gla‐100 group withdrew from the study because of AEs. Injection site reactions, none serious or resulting in treatment discontinuation, were reported in 8 participants (2.9%) in the Gla‐300 group and 4 participants (1.5%) in the Gla‐100 group.

Throughout the 12‐month on‐treatment period, the percentage of participants who were positive at any time for anti‐insulin antibodies was comparable between the Gla‐300 (89% \[237/266\]) and the Gla‐100 (87% \[235/270\]) groups. The percentage of participants who were negative for anti‐insulin antibodies at baseline, but positive later, was also comparable (74% \[72/97\] and 74% \[90/122\], respectively).

4. DISCUSSION {#dom13048-sec-0018}
=============

Here we report on the 12‐month period of observation for the EDITION 4 study. This nearly doubles the exposure of people with T1DM to Gla‐300 as compared to the 6‐month data,[10](#dom13048-bib-0010){ref-type="ref"} while maintaining the primary randomization, both vs Gla‐100 and between morning and evening injections in both treatment groups. The report thus includes considerably more tolerability and safety data than did the primary 6‐month study.[10](#dom13048-bib-0010){ref-type="ref"} The extension‐period data have also helped to identify longer‐term trends in glucose control, and allow hypoglycaemia rates that are less influenced by distortions in the period after randomization that resulted from beginning a new insulin treatment with which the investigators and participants had no prior experience.

In the equivalent basal and meal‐time insulin study in T2DM, EDITION 1, evolution of blood glucose control in the second 6‐month period showed a small but statistically significant advantage of Gla‐300 in change in HbA1c from baseline at 12 months.[8](#dom13048-bib-0008){ref-type="ref"} In EDITION 4, the change from baseline in HbA1c observed at 6 months remained comparable between Gla‐300 and Gla‐100 throughout the 12‐month study period (Figure [1](#dom13048-fig-0001){ref-type="fig"}C and Table [1](#dom13048-tbl-0001){ref-type="table-wrap"}). This finding is in line with that observed at 12 months in the basal and meal‐time insulin study in T1DM conducted in Japan, EDITION JP 1.[15](#dom13048-bib-0015){ref-type="ref"} However, for HbA1c in the morning vs evening injection groups in EDITION 4, which for Gla‐100 was comparable both at 6 and 12 months, for Gla‐300 there was a significantly larger decrease in favour of the morning group (Figure [1](#dom13048-fig-0001){ref-type="fig"}D). It should be noted that the morning injection groups used higher (basal and total) insulin doses than the evening injection groups, for both Gla‐300 and Gla‐100. The reason for this is not clear, and comparison of morning and evening injection schedules (a specified objective secondary to the overall comparison of the 2 insulins) is complicated by diurnal hormonal changes and differences in patterns of physical activity. Meal‐time insulin use may also be a contributing factor, although in this study very little titration of meal‐time insulin dose occurred. Of interest, a study in T1DM using continuous glucose monitoring (CGM) showed that Gla‐300 24‐hour glucose profiles did not differ, irrespective of basal insulin being administered in the morning or evening[16](#dom13048-bib-0016){ref-type="ref"}; a large ongoing study using CGM to investigate Gla‐300 and Gla‐100 given in the morning may provide further insights.[17](#dom13048-bib-0017){ref-type="ref"} The findings presented here highlight the value of longer‐term studies.

The 12‐month data from EDITION 4 showed that change in laboratory‐measured clinic FPG was comparable between the Gla‐300 and Gla‐100 groups. This measure, however, is not relevant to clinical practice as it requires people with T1DM to delay breakfast and breakfast insulin, something they are advised to avoid absolutely. Unfortunately, findings from the SMPG profiles are also unclear, in part because of baseline differences between the 2 treatment groups for the 3:00 [am]{.smallcaps} and pre‐breakfast glucose levels. However, endpoint findings at these times are similar (Figure [1](#dom13048-fig-0001){ref-type="fig"}G). There is some suggestion of separation between the Gla‐300 and Gla‐100 month‐12 SMPG profiles in the evening (bedtime) (Figure [1](#dom13048-fig-0001){ref-type="fig"}G), and this would seem to be confirmed by the data in Figure [1](#dom13048-fig-0001){ref-type="fig"}H, where SMPG profiles at 12 months for morning and evening injection are given. No separation of the 2 insulins at bedtime is seen for morning injection, while a separation can be perceived for evening injections in favour of Gla‐300. Speculatively, such a separation between insulins could be related to a failure of Gla‐100 to provide insulinization as effective as that of Gla‐300 in the hours immediately before the next injection, consistent with the comparative pharmacodynamic clamp data.[7](#dom13048-bib-0007){ref-type="ref"} As a caution, it should be noted that statistical testing of individual self‐monitored time points was not in the pre‐determined analysis plan, and profile interpretations are a matter of observation only.

The difficulty in interpreting morning and evening profiles illustrates a study limitation, namely, that the double comparison (two insulins, and morning versus evening) results in relatively small individual populations (\~140 people); consequently, each show relatively variable glucose profiles (Figure [1](#dom13048-fig-0001){ref-type="fig"}), particularly for laboratory‐measured clinic FPG and SMPG profiles. That said, for Gla‐300, which is expected from pharmacokinetic and pharmacodynamic studies, and notably from a CGM study, to be a true ≥24‐hour insulin,[7](#dom13048-bib-0007){ref-type="ref"}, [16](#dom13048-bib-0016){ref-type="ref"}, [18](#dom13048-bib-0018){ref-type="ref"} there should be no difference in glucose‐related outcomes between morning and evening. Any trend in morning injection control being better than that with evening injections could be explained by the higher dose used by the morning group.

Hypoglycaemia risks and rates did not differ between the 2 study insulins in any of the measures analysed (nocturnal/any time of day, confirmed or severe/documented symptomatic, thresholds of ≤3.9 or \<3.0 mmol/L, severe alone) (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"}). However, as is usual in this type of trial, EDITION 4 was not powered to detect differences in hypoglycaemia. Numerical differences in anytime (24 hours) severe hypoglycaemia event rates, which do not approach statistical significance, can be explained by the fact that 1 participant in the Gla‐300 group reported 42 severe daytime events during the extension period. Cumulative event curves support the rate ratio data in revealing no differences between Gla‐300 and Gla‐100, but there is a trend to divergence of anytime events in the second 6‐month period, which needs further study (Figure [2](#dom13048-fig-0002){ref-type="fig"}). These findings differ from those of the EDITION JP 1 study, which investigated evening basal insulin injections; in that study Gla‐300 was associated with a lower risk and rate of nocturnal (0:00--05:59 [am]{.smallcaps}) confirmed (\<3.0 mmol/L \[\<54 mg/dL\]) or severe hypoglycaemia vs Gla‐100.[15](#dom13048-bib-0015){ref-type="ref"} They also differ from results with another long‐acting insulin (insulin degludec) in T1DM when given as an evening injection, which show lower rates of nocturnal hypoglycaemia with insulin degludec vs Gla‐100.[19](#dom13048-bib-0019){ref-type="ref"}, [20](#dom13048-bib-0020){ref-type="ref"} However, of note, a trial‐level meta‐analysis of degludec and Gla‐100 in T2DM suggests less reduction in HbA1c with degludec.[21](#dom13048-bib-0021){ref-type="ref"} When Gla‐300 is used in T2DM, an advantage over Gla‐100 was found, both in the basal plus meal‐time study to 1 year,[8](#dom13048-bib-0008){ref-type="ref"} and in the patient‐level meta‐analysis of 3 international studies in T2DM.[22](#dom13048-bib-0022){ref-type="ref"} In both the present study and the degludec studies, nocturnal hypoglycaemia rates remain clinically important even with the new insulins, emphasizing that flat true ≥24‐hour insulin profiles still suffer from lack of the minute‐to‐minute control of insulin delivery that is needed physiologically to eliminate the risk of hypoglycaemia.[23](#dom13048-bib-0023){ref-type="ref"}

Reported AEs over 12 months were similar in the 2 groups; most would be background noise.[10](#dom13048-bib-0010){ref-type="ref"}, [24](#dom13048-bib-0024){ref-type="ref"} Data concerning serious AEs, whether overall or when analysed by organ and term (data not shown), did not reveal any signal of concern, and injection site reactions did not differ between treatment groups. As noted previously,[10](#dom13048-bib-0010){ref-type="ref"} the circulating active metabolite of glargine is the same for Gla‐300 as for the familiar and much‐tested Gla‐100.

The study limitations are generally inherent to clinical studies of this kind in people with T1DM. Confounding of glucose control and, particularly, hypoglycaemia may occur through the use and titration of meal‐time insulins, and while doses of these did not differ between treatment groups at 6 months, they were slightly different at 12 months (Figure [1](#dom13048-fig-0001){ref-type="fig"}A). This is relevant, as the majority of hypoglycaemic events occurred during the day rather than at night (Table [2](#dom13048-tbl-0002){ref-type="table-wrap"} and Figure [2](#dom13048-fig-0002){ref-type="fig"}). HbA1c reduction was less in this study than that seen in a study of insulin degludec.[20](#dom13048-bib-0020){ref-type="ref"} It is not clear if this is related to the population studied or the insulin dose titration, but it may have limited statistical power to show differences in hypoglycaemia event rates. In addition, the discontinuation rate in this study was higher than is desirable, although this was matched between the Gla‐300 and Gla‐100 groups. While our study groups are perhaps typical of a modern T1DM population, the relatively high mean age and BMI, and the total insulin dose, may mean that the results are less generalizable to younger or leaner people.

In conclusion, at 12 months the results of the EDITION 4 clinical trial suggest that, in people with T1DM of long duration studied in a range of countries, Gla‐300 has glucose control properties similar to those of Gla‐100, albeit with a somewhat higher dose requirement. There was no evidence of new tolerability or safety issues over the 12 months of exposure. Comparison between morning and evening injection suggests little difference in glucose profiles and no difference in hypoglycaemia or AEs for Gla‐300, consistent with pharmacokinetic/pharmacodynamic data. These findings imply that the timing of Gla‐300 injection can be flexible, allowing injection at any time of day. More complete assessment of glucose profiles provided by the use of CGM may better determine the relative benefits of Gla‐300 over Gla‐100, and facilitate better management of meal‐time insulin in the context of a more stable basal insulin effect. Furthermore, studies in routine clinical practice may help evaluate the advantage to users of morning rather than evening injection of the basal insulin.
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